e13a2 | e14a2 | p value | |
---|---|---|---|
Number | |||
% | 29% | 71.0% | n/a |
Exact | 20 | 49 | |
Age (years) | |||
Mean | 45.0 | 54.57 | 0.043 |
Median | 46.0 | 59.0 | |
Range | 4–81 | 5–80 | |
Sex | |||
Male | 75.0% | 55.1% | 0.125 |
Female | 25.0% | 44.9% | |
Follow-up (months) | |||
Mean | 33.85 | 27.24 | 0.192 |
Median | 37.5 | 23 | |
Range | 1–70 | 3–76 | |
Haemoglobin (g/l) | |||
Mean | 113.5 | 121.3 | 0.134 |
Range | 86–148 | 64–158 | |
White Cell Count | |||
(×109/l) | 189.80 | 92.40 | 0.0002 |
Mean | 49.1–563 | 4.86–292 | |
Range | |||
Platelets (×109/l) | |||
Mean | 308 | 644 | 0.001 |
Range | 93–1058 | 178–2507 | |
EUTOS SCORE | |||
Number available | 15 | 42 | 0.685 |
Average Score | 35.93 | 39.66 | |
% High Risk | 5.0% | 6.1% | |
BCR-ABL1 PCR level | |||
Number available | 17 | 42 | 0.354 |
Mean | 58.64% | 71.0% | |
Range | 25.6–112 | 8.1–344 | |
Initial Treatment | |||
Imatinib 400 mg/day | 90% | 93.9% | n/a |
Imatinib 300 mg/day | 5% | 0% | |
Imatinib 200 mg/day | 5% | 6.1% |